Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics

[1]  H. Atkins,et al.  Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[3]  Steven J. M. Jones,et al.  Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. , 2012, The New England journal of medicine.

[4]  C. Greenwood,et al.  Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours , 2011, PloS one.

[5]  A. Walker,et al.  Prolactin increases survival and migration of ovarian cancer cells: importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists. , 2011, Cancer letters.

[6]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[7]  E. Jacobson,et al.  Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor , 2010, Trends in Endocrinology & Metabolism.

[8]  K. Azarow,et al.  Small Cell Ovarian Carcinoma: A Rare, Aggressive Tumor Masquerading as Constipation in a Teenager With a Fatal Outcome , 2010, Journal of pediatric hematology/oncology.

[9]  H. Tsuda,et al.  Cumulative alterations of p27Kip1‐related cell‐cycle regulators in the development of endometriosis‐associated ovarian clear cell adenocarcinoma , 2010, Histopathology.

[10]  K. Busam,et al.  An Immunohistochemical Study of Cervical Neuroendocrine Carcinomas: Neoplasms That are Commonly TTF1 Positive and Which May Express CK20 and P63 , 2010, The American journal of surgical pathology.

[11]  D. Kirn,et al.  Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. , 2010, Cytokine & growth factor reviews.

[12]  J. Petty,et al.  Familial small cell carcinoma of the ovary , 2009, Pediatric blood & cancer.

[13]  Z. Jehan,et al.  Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer , 2009, Laboratory Investigation.

[14]  Steven J. M. Jones,et al.  Circos: an information aesthetic for comparative genomics. , 2009, Genome research.

[15]  Yonghong Xiao,et al.  GOLPH3 modulates mTOR signaling and rapamycin sensitivity in cancer , 2009, Nature.

[16]  K. Yao,et al.  The autocrine human secreted PDZ domain-containing protein 2 (sPDZD2) induces senescence or quiescence of prostate, breast and liver cancer cells via transcriptional activation of p53. , 2008, Cancer letters.

[17]  Tadao Tanaka,et al.  Establishment and characterization of a human ovarian small cell carcinoma, hypercalcemic type, cell line (OS-1) secreting PTH, PTHrP and ACTH-special reference to the susceptibility of anti-cancer drugs- , 2008, Human Cell.

[18]  H. Atkins,et al.  Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis , 2008, Proceedings of the National Academy of Sciences.

[19]  A. Mes-Masson,et al.  Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines , 2008, BMC Medical Genomics.

[20]  M. Pagano,et al.  Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer , 2008, Nature Reviews Cancer.

[21]  N. Jahchan,et al.  A La-related protein modulates 7SK snRNP integrity to suppress P-TEFb-dependent transcriptional elongation and tumorigenesis. , 2008, Molecular cell.

[22]  F. Mayer,et al.  Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  D. Kirn,et al.  Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. , 2007, The Journal of clinical investigation.

[24]  Anne-Marie Mes-Masson,et al.  Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC) , 2007, Molecular carcinogenesis.

[25]  M. Nucci,et al.  Biomarker‐assisted diagnosis of ovarian, cervical and pulmonary small cell carcinomas: the role of TTF‐1, WT‐1 and HPV analysis , 2007, Histopathology.

[26]  J. Bell,et al.  Oncolytic viruses: what's next? , 2007, Current cancer drug targets.

[27]  D. Kirn,et al.  From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. , 2007, Current cancer drug targets.

[28]  Jiong Wu,et al.  Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis. , 2006, European journal of cancer.

[29]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[30]  Yasuo Watanabe,et al.  Clinical significance of Skp2 expression, alone and combined with Jab1 and p27 in epithelial ovarian tumors. , 2006, Oncology reports.

[31]  J. Ledermann,et al.  Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study. , 2006, Gynecologic oncology.

[32]  J. Bell,et al.  Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.

[33]  Pascal Reynier,et al.  Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. , 2005, The Journal of clinical endocrinology and metabolism.

[34]  P. Clement,et al.  Selected miscellaneous ovarian lesions: small cell carcinomas, mesothelial lesions, mesenchymal and mixed neoplasms, and non-neoplastic lesions , 2005, Modern Pathology.

[35]  L. Cope,et al.  Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With Immunohistochemical Correlation , 2005, The American journal of surgical pathology.

[36]  E. Oliva,et al.  An Immunohistochemical Analysis of Ovarian Small Cell Carcinoma of Hypercalcemic Type , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[37]  H. Atkins,et al.  Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. , 2004, Human gene therapy.

[38]  T. Hudson,et al.  Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogenously staining region , 2004, Molecular carcinogenesis.

[39]  S. Yamada,et al.  Stage IIIC Small Cell Carcinoma of the Ovary: Survival With Conservative Surgery and Chemotherapy , 2004, Obstetrics and gynecology.

[40]  K. Shigemasa,et al.  Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  P. Santamaria,et al.  Regulation of larval hematopoiesis in Drosophila melanogaster: a role for the multi sex combs gene. , 2002, Genetics.

[42]  M. Spycher,et al.  Hypercalcemic-type of small cell carcinoma of the ovary: characterization of a new tumor line. , 2001, Anticancer Research.

[43]  M. Rubin,et al.  Activated in prostate cancer: a PDZ domain-containing protein highly expressed in human primary prostate tumors. , 2001, Cancer research.

[44]  T. Fukuda,et al.  Hypercalcemia due to parathyroid hormone-related protein produced by primary ovarian clear cell adenocarcinoma: case report. , 2000, Gynecologic oncology.

[45]  S. Goodman,et al.  PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. , 1999, The American journal of pathology.

[46]  J. Foekens,et al.  Genetic alterations in ovarian borderline tumours and ovarian carcinomas. , 1999, European journal of obstetrics, gynecology, and reproductive biology.

[47]  R. McCoy,et al.  UTERINE AND OVARIAN CONSERVATION IN ADVANCED SMALL CELL CARCINOMA OF THE OVARY , 1998, Obstetrics and gynecology.

[48]  F. Cappuccini,et al.  Advanced-stage small cell carcinoma of the ovary in pregnancy: long-term survival after surgical debulking and multiagent chemotherapy. , 1997, Gynecologic oncology.

[49]  A. Villanueva,et al.  K‐ras mutations in mucinous ovarian tumors , 1997, Cancer.

[50]  Thomas Ried,et al.  Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping , 1997, Nature Genetics.

[51]  Y. Tachimori,et al.  Circulating parathyroid hormone-related protein (109-141) in malignancy-associated hypercalcemia. , 1996, Japanese journal of clinical oncology.

[52]  A. Cohen,et al.  A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. , 1995, Blood.

[53]  E. Oliva,et al.  Small Cell Carcinoma of the Ovary, Hypercalcemic Type: A Clinicopathological Analysis of 150 Cases , 1994, The American journal of surgical pathology.

[54]  E. Chen,et al.  A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. , 1987, Science.

[55]  S. Krane,et al.  Differential cyclic AMP responses to calcitonin among human ovarian carcinoma cell lines: A calcitonin‐responsive line derived from a rare tumor type , 1986, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[56]  M. Winker,et al.  Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. , 1985, Cancer research.

[57]  B. Vanderhyden,et al.  Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. , 2007, Experimental cell research.

[58]  A. C. Webb,et al.  Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[59]  R. Scully,et al.  Small cell carcinoma of the ovary with hypercalcemia: A report of eleven cases , 1982, Cancer.